HuidaGene Therapeutics
PrivateLast Round
Series C
May 1, 2022
Company Overview
HuidaGene Therapeutics is a biotechnology company that develops CRISPR-based gene-editing and RNA-targeting therapies for the treatment of severe genetic diseases in neurology, ophthalmology, and neuromuscular fields.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HuidaGene Therapeutics Comparables
Compare HuidaGene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| YolTech Therapeutics | 83% | |
| Neurophth | 81% | |
| Intellia Therapeutics | 78% | |
HuidaGene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 1, 2022 | ||||
| Series B | May 1, 2021 | ||||
| Series A | Nov 1, 2019 | ||||
| Angel | Nov 1, 2018 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 7, 2025
Monthly visitors grew 245% MoM to 6.9K.
- May 1, 2022
Raised Series C round
HuidaGene Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about HuidaGene Therapeutics's valuation, stock price, and market status.